Skip to Content

GI Cancer Clinical Trials


NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy  with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (DMMR) Metastatic Colorectal Cancer
Aims: The purpose of this study is to compare any good and bad effects of using chemotherapy alone compared to chemotherapy and an investigational new drug, Atezolizumab.
Diagnosis: Colorectal Cancer
Principal Investigator:
 Robert Marsh, MD
IRB Approval Number: EH18-189
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment:
Yes

Novacure PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma
Aims: The purpose of this study is to see if adding this device for patients getting chemotherapy and after treatment helps prevent the cancer from recurring.
Diagnosis: Pancreatic Cancer
Principal Investigator:
 Marisa Hill, MD
IRB Approval Number: EH19-006
Sponsor: Novacure
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment:
Yes

A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Aims: The purpose of this study is to compare any good and bad effects of using chemotherapy alone compared to chemotherapy and the drug atezolizumab and to see if adding atezolizumab will reduce the chances of your cancer from coming back.
Diagnosis: Colon Cancer
Principal Investigator:
 Robert Marsh, MD
IRB Approval Number: EH18-329
Sponsor: Alliance in Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

The Pancreatic Sample Repository
Aims: Collect blood, pancreatic secretions and pancreatic tissue from patients undergoing surgery for pancreatic diseases, including cancer and store these samples in a repository for future studies done at NorthShore or at collaborating institutions
Diagnosis: Any pancreatic disease
Principal Investigator: Karen Kaul, MD 
IRB Approval Number: EH02-186
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Susan Jane Stocker, LPN, BLS, CCRP at 847.570.1322, sstocker@northshore.org or Gnathan Carpenter, RN at 847.570.2949, gcarpenter@northshore.org
Open to Enrollment: Yes

Clinical Pancreatic Cancer Database
Aims: Capture, review, and compare medical information, including symptoms, treatments, and complications that people with pancreatic diseases have and store this information for future research studies done at NorthShore or with collaborating institutions.
Diagnosis: Any pancreatic disease
Principal Investigator: Mark S. Talamonti, MD
IRB Approval Number: EH08-197T
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Susan Jane Stocker, LPN, BLS, CCRP at 847.570.1322, sstocker@northshore.org or Gnathan Carpenter, RN at 847.570.2949, gcarpenter@northshore.org
Open to Enrollment: Yes

Isofol: ISO-CC-007: A Randomized, Multicenter, Parallel-Group, Phase III Study to Compare the Efficacy of Artfolitixorin Versus Leucovorin in Combination with 5-Fluorouracil, Oxaliplatin, and Bevacizumab in Patients with Advanced Colorectal Cancer
Aims: 
The purpose of this study is to compare arfolitixorin to leucovorin in patients receiving chemotherapy for colon cancer.
Diagnosis: Colorectal Cancer
Principal Investigator: Marisa Hill, MD
IRB Approval Number: EH19-065
Sponsor: Isofol
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698

EA2165: Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High-Risk Anal Cancer

Aims: The purpose of this study is to see if Nivolumab is helpful in reducing the risk of recurrence of anal cancer.
Diagnosis: Anal Cancer
Principal Investigator: Marisa Hill, MD
IRB Approval Number: EH19-071
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes     

RTOG 1112: Randomized Phase III Study of Sorafenib Versus Sterotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Aims: The purpose of the study is to compare the effects of sorafenib alone (present standard of care treatment) to radiation followed by sorafenib.
Diagnosis: Hepatocellular Cancer (Liver cancer)
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH19-068
Sponsor: RTOG
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment:
 Yes